CLAIM AMENDMENTS

1. (Currently Amended) A composition comprising a ~~preselected population of~~ lymphocytes having (i) a chimeric receptor or a T-cell receptor, either of which is reactive with a tumor antigen, and (ii) an endogenous T-cell receptor reactive with a cell, which is allogeneic to the lymphocyte ~~a preselected strong antigen, wherein the preselected strong antigen is an allogeneic agent~~.

2. Cancelled

3. (Currently Amended) The composition of claim 1, wherein the lymphocytes ~~are~~ is a T-cells.

4. (Currently Amended) The composition of claim 1, wherein the tumor antigen is an ~~derived from~~ ovarian ~~cancer~~ tumor antigen.

5. Cancelled

6. (Currently Amended) The composition of claim 1, wherein the chimeric receptor is a recombinant protein.

7. (Currently Amended) The composition of claim 1, wherein the chimeric receptor comprises ~~is~~ a single chain Fv receptor.

8. (Currently Amended) The composition of claim 1, wherein the ~~strong antigen~~ cell ~~comprises~~ is a ~~allogeneic~~ peripheral blood mononuclear cells.

9. Cancelled

10. (Currently Amended) The composition of claim ~~1~~ 4, wherein the chimeric receptor is Mov-~~yy~~.

11. (Currently Amended) A lymphocyte having a T-cell receptor reactive with ~~an~~ cell, which is allogeneic to the lymphocyte, ~~agent~~ and a chimeric receptor reactive with a tumor antigen.

12. Cancelled.

13-14. Cancelled.

15. Cancelled.

16-39. Cancelled.

40. (Currently Amended) A pharmaceutical composition comprising:

a ~~population of~~ lymphocytes containing a chimeric receptor reactive with a tumor antigen and ~~preselected for reactivity~~ an endogenous T-cell receptor reactive with ~~a strong antigen, wherein the strong antigen is an allogeneic agent~~ a cell, which is allogeneic to the lymphocyte; and

a pharmaceutically acceptable carrier.

41. (Currently Amended) A method of preparing ~~preselected dual specificity~~ lymphocytes having dual antigen specificity comprising:

~~selecting for~~ contacting lymphocytes ~~reactive with a strong antigen ex vivo, wherein the strong antigen is an allogenic agent~~ with a cell, which is allogeneic to the lymphocytes; and

transducing the lymphocytes with a chimeric receptor gene, said gene encoding a chimeric receptor, which is reactive with a tumor antigen.

42. Cancelled.

43. Cancelled.

44. (New) The composition of claim 4, wherein the ovarian tumor antigen is folate binding protein (FBP).

45. (New) The composition of claim 1, wherein the lymphocyte is a human lymphocyte.

46. (New) The composition of claim 1, wherein the cell is a splenocyte or a dendritic cell.

47. (New) The lymphocyte of claim 11, wherein the lymphocyte is a human lymphocyte.

48. (New) The lymphocyte of claim 11, wherein the tumor antigen is an ovarian tumor antigen.

49. (New) The lymphocyte of claim 48, wherein the ovarian tumor antigen is FBP.

50. (New) The lymphocyte of claim 11, wherein the cell is a peripheral blood mononuclear cell or a splenocyte.

51. (New) The lymphocyte of claim 11, wherein the chimeric receptor is Mov-γ.

52. (New) The pharmaceutical composition of claim 40, wherein the lymphocyte is a human lymphocyte.

53. (New) The pharmaceutical composition of claim 40, wherein the chimeric receptor is Mov-γ.

54. (New) The pharmaceutical composition of claim 40, wherein the tumor antigen is an ovarian tumor antigen.

55. (New) The pharmaceutical composition of claim 53, wherein the ovarian tumor antigen is FBP.

56. (New) The pharmaceutical composition of claim 40, wherein the cell is a peripheral blood monuclear cell, a splenocyte, or a dendritic cell.

57. (New) The method of claim 41, wherein the chimeric receptor is Mov-γ.

58. (New)The method of claim 41, wherein the cell is a peripheral blood mononuclear cell, a splenocyte, or a dendritic cell.

59. (New) The method of claim 41, wherein the tumor antigen is an ovarian tumor antigen.

60. (New) The method of claim 59, wherein the ovarian tumor antigen is FBP.

61. (New) The method of claim 41, wherein the lymphocytes are human lymphocytes.

62. (New) An isolated or purified human lymphocyte having a chimeric receptor reactive with a tumor antigen and a T-cell receptor reactive with an antigen that is not a tumor antigen.

63. (New) The isolated or purified human lymphocyte of claim 62, wherein the tumor antigen is an ovarian tumor antigen.

64. (New) The isolated or purified human lymphocyte of claim 63, wherein the ovarian tumor antigen is FBP.

65. (New) The isolated or purified human lymphocyte of claim 62, wherein the antigen that is not a tumor antigen is on a cell, which is allogeneic to the human lymphocyte.

66. (New) The isolated or purified human lymphocyte of claim 65, wherein the cells is a peripheral blood mononuclear cell, a splenocyte, or a dendritic cell.

67. (New) The isolated or purified human lymphocyte of claim 62, wherein the chimeric receptor is Mov-γ.

68. (New) A composition comprising the isolated or purified human lymphocyte of claim 62.

69. (New) A pharmaceutical composition comprising the isolated or purified human lymphocyte of claim 62.

70. (New) A method of preparing human lymphocytes having dual antigen specificity comprising:

contacting human lymphocytes with an antigen that is not a tumor antigen; and

transducing the human lymphocytes with a chimeric receptor gene, said gene encoding a chimeric receptor, which is reactive with a tumor antigen.